Nancy A. Simonian M.D.
Net Worth

Last updated:

What is Nancy A. Simonian M.D. net worth?

The estimated net worth of Dr. Nancy A. Simonian M.D. is at least $7,255,730 as of 2 Dec 2024. He owns shares worth $22 as insider, has earned $45,708 from insider trading and has received compensation worth at least $7,210,000 in Syros Pharmaceuticals, Inc..

What is the salary of Nancy A. Simonian M.D.?

Dr. Nancy A. Simonian M.D. salary is $1,030,000 per year as Pres, Chief Executive Officer & Director in Syros Pharmaceuticals, Inc..

How old is Nancy A. Simonian M.D.?

Dr. Nancy A. Simonian M.D. is 64 years old, born in 1961.

What stocks does Nancy A. Simonian M.D. currently own?

As insider, Dr. Nancy A. Simonian M.D. owns shares in one company:

Company Title Shares Price per share Total value
Syros Pharmaceuticals, Inc. (SYRS) Pres, Chief Executive Officer & Director 4,000 $0.01 $22

What does Syros Pharmaceuticals, Inc. do?

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS logo
SYRS
Syros Pharmaceuticals, Inc.
$0.01

Nancy A. Simonian M.D. insider trading

Syros Pharmaceuticals, Inc.

Dr. Nancy A. Simonian M.D. has made 2 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 37,070 units of SYRS stock worth $10,009 on 2 Dec 2024.

The largest trade he's ever made was exercising 134,713 units of SYRS stock on 25 Nov 2024. As of 2 Dec 2024 he still owns at least 4,000 units of SYRS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 37,070 $0.27 $10,009
Sale
Common Stock 134,713 $0.27 $35,699
Option
Restricted Stock Units 40,125 N/A N/A
Option
Common Stock 40,125 N/A N/A
Option
Common Stock 40,125 N/A N/A
Option
Restricted Stock Units 40,125 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Restricted Stock Units 6,000 N/A N/A
Option
Stock Option (right to buy) 29,917 N/A N/A
Option
Common Stock 29,917 N/A N/A
Option
Common Stock 29,917 $7.21 $215,791
Option
Stock Option (right to buy) 52,401 N/A N/A
Option
Common Stock 52,401 N/A N/A
Option
Common Stock 110,588 N/A N/A
Option
Stock Option (right to buy) 110,588 $1.35 $149,294
Option
Stock Option (right to buy) 110,588 N/A N/A

Syros Pharmaceuticals key executives

Syros Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: